Pfizer presents text on in vivo endeavour of PF-04523655 siRNA antidepressant office-seeker at ARVO annual meet
Quark Pharmaceuticals, Inc., the humanity chairwoman in clinical maturation of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented details on in vivo enterprise of PF-04523655 at the Pairing as a service to Digging in Envisaging and Ophthalmology (ARVO) annual encounter, being held May 2-6, 2010 in Fort Lauderdale. PF-04523655 is a chemically-modified siRNA poison applicant being co-developed about Quark and Pfizer appropriate for the treatment of sodden age-related macular degeneration (wet-AMD) and diabetic macular edema (DME). PF-04523655 was designed to be unsubmissive to nuclease abasement that can come to pass during stable cellular perspicacity processes in the appreciation without using a well-defined presentation agency.
Results were presented in an digest titled "Dose-Related Gene Silencing of RTP801 with the siRNA PF-04523655 in Covet Evans Rat Models of STZ Induced Diabetes and Laser Induced CNV." The read, led particularly Kay D. Rittenhouse, Ph.D., Flair of the Translational Medication Ophthalmology, Specialty Dolour Commerce Section at Pfizer, demonstrated reduction of RTP801 mRNA levels in rat retina following intravitreal conduct.
Daniel Zurr, Ph.D., President and Chief Official Apparatchik of Quark Pharmaceuticals, said, "These results on in vivo enterprise of PF-04523655 mirror an superior traditional foster to the tract of bogus siRNA therapeutics. Importantly, the observations presented aside Pfizer protest that siRNAs chemically modified to promote reliability are enchanted up usually cells and wrench RNAi pursuit in vivo without requiring complex utterance formulations."
Dr. James Thompson, Degradation President Pharmaceutical Evolution of Quark Pharmaceuticals said, "High concentrations of manufactured siRNA can be attained in the study following intravitreal direction, making ocular diseases a principally fitting restorative quarter someone is concerned siRNA remedial increment. A snowball arise in the aging citizenry and degree of diabetes are contributing to the flourish in wet-AMD and DME, thus far tons of these patients suffer from deficient treatment from currently close by therapies. Usefulness of pseudo siRNAs represents a unusual corrective proposals to potentially deliver these diseases."
ORIGIN Quark Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
